12 Questions
Which cytokine has been identified as a key mediator in the inflammatory processes of acute gout flares and bone destruction?
Interleukin-1
What type of drug has been tested as a potential treatment for acute gout?
Anakinra, a recombinant form of the human interleukin-1 receptor antagonist
What is a potential future agent for the treatment of gout?
Lesinurad, a uricosuric drug
What are some of the limitations of current medications for gout?
Limited efficacy, hypersensitivity reactions, frequent monitoring, and risk of accumulation in patients with renal impairment
What is a novel therapeutic target that has been identified in the understanding of gout and hyperuricemia?
Interleukin-1ß
What is the primary focus of future directions in gout pharmacotherapy according to the text?
Developing novel agents based on new therapeutic targets
What is the key step in processing IL-1ß from its pro-form to active cytokine?
Activation of the NALP3 inflammasome
Which of the following is an IL-1 blocker with a longer half-life that is under investigation in gout?
Canakinumab
What is the key determinant of increased serum urate levels?
Increased expression of URAT1
Which enzyme is a potential therapeutic target for gout due to its role in guanine nucleotide biosynthesis?
Inosine 5'-monophosphate dehydrogenase (IMPDH)
Which approach can select the best treatment in specific patient phenotypes in a shorter time span than testing every phenotype in a separate trial?
Adaptive trial design
What is a major limitation of the traditional approach of using the same dose of a drug for all patients?
All of the above
Explore the role of interleukin-1 and other cytokines in the inflammatory processes of gout, as well as the potential treatment options such as anakinra. Learn about available drugs that target interleukin-1 and their implications for future gout treatment.
Make Your Own Quizzes and Flashcards
Convert your notes into interactive study material.
Get started for free
